Aniline

Aniline

SCHEMBL2018487

CC(O)NS(N)(=O)=O.Nc1ccccc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
ACHE P22303 3/20 0.44
TSHR P16473 1/20 0.41
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP7 P09237 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GMNN O75496 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
PMP22 Q01453 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337087 0.79
SCHEMBL1408449 0.79
Aniline SCHEMBL3783271 0.75 TSHR (0.58) CA1CA2TSHRMMP1MMP2
Aniline SCHEMBL28215920 0.75 TSHR (0.65) TSHRALDH1A1KMT2ALMNAKDM4E
Aniline SCHEMBL11592246 0.75 TSHR (0.65) TSHRALDH1A1KMT2ALMNAKDM4E
Aniline SCHEMBL3156113 0.73 TSHR (0.61) CA1CA2TSHRALDH1A1KMT2A
Aniline SCHEMBL11023750 0.73 TSHR (0.61) TSHRALDH1A1KMT2ALMNAKDM4E
Aniline SCHEMBL4582474 0.72 TSHR (0.69) CA1CA2TSHRKMT2ALMNA
Aniline SCHEMBL9183539 0.71 TP53 (0.52) TSHRALDH1A1LMNAKDM4ENPC1
SCHEMBL3376830 0.71 CA1 (0.62) CA1CA2ACHEALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102131815-B Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate TIBOTEC PHARMACEUTICALS (IE) 2014-10-15 CN disclosed
EP-2346877-B1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE JANSSEN R & D IRELAND (IE) 2014-08-20 EP disclosed
US-8580981-B2 Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate JANSSEN R&D IRELAND (IE) 2013-11-12 US disclosed
CN-1898248-B Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD 2011-08-17 CN disclosed
EP-2346877-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE Tibotec Pharmaceuticals (IE) 2011-07-27 EP disclosed
CN-102131815-A Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate TIBOTEC PHARM LTD 2011-07-20 CN disclosed
US-20110160468-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE JANSSEN SCIENCES IRELAND UC (IE) 2011-06-30 US disclosed
CN-101820865-A anti-HIV tablet formulation comprising darunavir TIBOTEC PHARM LTD 2010-09-01 CN disclosed
US-7772411-B2 Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-08-10 US disclosed
US-20100189783-A1 RELATING TO ANTI-HIV TABLET FORMULATIONS JANSSEN PHARMACEUTICA NV (BE) 2010-07-29 US disclosed
WO-2010023322-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARMACEUTICALS (IE) 2010-03-04 WO disclosed
EP-1725566-B1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARM LTD (IE) 2009-06-17 EP disclosed
US-20070060642-A1 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate JANSSEN SCIENCES IRELAND UC (IE) 2007-03-15 US disclosed
CN-1898248-A Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD (IE) 2007-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189783-A1 RELATING TO ANTI-HIV TABLET FORMULATIONS SRI, CD4, SORD CA1 2070/4885CA2 3747/4885ACHE 1089/4885
US-20110160468-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE HTR3C, HPD, HAAO CA1 3626/4885CA2 3095/4885ACHE 833/4885
US-20070060642-A1 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate HPD, HTR3C, HAAO CA1 3293/4885CA2 2351/4885ACHE 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.